for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inovio Pharmaceuticals Inc

INO.O

Latest Trade

2.31USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.92

 - 

5.47

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.31
Open
--
Volume
--
3M AVG Volume
13.12
Today's High
--
Today's Low
--
52 Week High
5.47
52 Week Low
1.92
Shares Out (MIL)
99.03
Market Cap (MIL)
241.63
Forward P/E
-2.35
Dividend (Yield %)
--

Next Event

Inovio Pharmaceuticals Inc at Stifel Healthcare Conference

Latest Developments

More

Inovio Pharmaceuticals Reports Third Quarter Results

Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (Gbm) Study With Ino-5401 In Combination With Pd-1 Inhibitor Libtayo (Cemiplimab)

Inovio Pharmaceuticals Reports Q2 Loss Per Share $0.30

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Industry

Biotechnology & Drugs

Contact Info

6769 Mesa Ridge Rd

+1.858.4103134

http://www.inovio.com/

Executive Leadership

Simon X. Benito

Independent Chairman of the Board

Jong Joseph Kim

President, Chief Executive Officer, Director

Peter D. Kies

Chief Financial Officer

Jacqueline Elizabeth Shea

Chief Operating Officer

Laurent M. Humeau

Chief Scientific Officer

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.010

2017

-1.080

2018

-1.050

2019(E)

-1.059
Price To Earnings (TTM)
--
Price To Sales (TTM)
32.35
Price To Book (MRQ)
4.49
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
117.05
LT Debt To Equity (MRQ)
117.05
Return on Investment (TTM)
-90.38
Return on Equity (TTM)
-74.42

Latest News

Latest News

BRIEF-Inovio Opens Trial To Test Its VGX-3100 Drug In HPV Patients

* INOVIO OPENS PHASE 2 TRIAL FOR VGX-3100 IN THIRD INDICATION TO TREAT HPV – THE NO. 1 SEXUALLY TRANSMITTED DISEASE

BRIEF-Inovio Says HIV Vaccine Maintained Immune Responses One Year After Start Of Trial

* INOVIO HIV VACCINE, WHICH GENERATED NEAR 100% IMMUNE RESPONSES, SUSTAINED DURABLE MEMORY RESPONSES MEASURED ONE YEAR AFTER THE START OF CLINICAL TRIAL Source text for Eikon: Further company coverage:

BRIEF-Inovio Pharmaceuticals Q1 Loss Per Share $0.36

* INOVIO PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

BRIEF-Inovio Pharmaceuticals Says For Qtr Ended March 31, Net Loss Per Share Was $0.36

* INOVIO PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, NET LOSS PER SHARE WAS $0.36 - SEC FILING

BRIEF-Inovio Awarded Up To $56 Million From Cepi To Advance Dna Vaccines Against Lassa Fever And Mers

* INOVIO AWARDED UP TO $56 MILLION FROM CEPI TO ADVANCE DNA VACCINES AGAINST LASSA FEVER AND MERS

BRIEF-Inovio Closes License And Collaboration Agreement With ApolloBio To Develop And Commercialize VGX-3100 In Greater China

* INOVIO CLOSES LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

BRIEF-Inovio Pharmaceuticals Reports Qtrly ‍Net Loss Attributable To Stockholders Of $0.24 Per Basic Share​

* INOVIO PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

BRIEF-Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

* INOVIO'S DNA IMMUNOTHERAPY DEMONSTRATES IMMUNE RESPONSE RESULTS KEY IN TREATING CHRONIC HEPATITIS B INFECTION Source text for Eikon: Further company coverage:

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS

BRIEF-Inovio Receives Milestone Payment From Medimmune

* INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2 Source text for Eikon: Further company coverage:

BRIEF-Inovio Enters License, Collaboration Agreement With Apollobio To Develop, Commercialize VGX-3100 In Greater China

* INOVIO ENTERS LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

BRIEF-‍Inovio Pharma Cancer Vaccine Shows Promise In Preclinical Trial

* INOVIO PHARMACEUTICALS SYNCON TERT CANCER IMMUNOTHERAPY COMBINED WITH CHECKPOINT INHIBITOR SYNERGISTICALLY SHRINKS TUMOR,IMPROVES SURVIVAL IN PRECLINICAL TUMOR MODEL Source text for Eikon: Further company coverage:

BRIEF-Inovio pharmaceuticals reports 2017 third quarter financial results

* Inovio Pharmaceuticals reports 2017 third quarter financial results

BRIEF-Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

* Inovio Pharmaceuticals says on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

BRIEF-Inovio Pharma initiates immuno-oncology clinical study for glioblastoma

* Inovio Pharmaceuticals initiates immuno-oncology clinical study for glioblastoma in combination with Regeneron’S PD-1 inhibitor Source text for Eikon: Further company coverage:

BRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine

* Inovio Pharmaceuticals Inc reported on positive safety and immune response results from phase 1 trial of a vaccine against zika virus

BRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

* Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

BRIEF-Inovio’s cancer immunotherapy slowed PSA rise and increased PSA doubling times in patients with recurrent prostate cancer

* Inovio’s cancer immunotherapy (ino-5150) slowed PSA rise and significantly increased psa doubling times in patients with recurrent prostate cancer

BRIEF-Inovio Pharmaceuticals reports Q2 loss per share $0.13

* Inovio Pharmaceuticals reports 2017 second quarter financial results

BRIEF-Inovio Pharmaceuticals prices 12.5 mln share offering at $6 per share

* Inovio announces pricing of public offering of common stock

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up